Wide-field radiation therapy alone or with chemotherapy for Hodgkin's disease in relapse from combination chemotherapy.

1987 ◽  
Vol 5 (4) ◽  
pp. 544-549 ◽  
Author(s):  
P Mauch ◽  
N Tarbell ◽  
A Skarin ◽  
D Rosenthal ◽  
H Weinstein

Nineteen patients with Hodgkin's disease who relapsed primarily in nodal sites after intensive combination chemotherapy were retreated with wide-field radiation therapy alone or with additional chemotherapy between January 1971 and December 1984. Six patients presented in second relapse and 13 patients in first relapse. Seven patients were treated with combination chemotherapy and radiation therapy and twelve patients were treated with radiation therapy alone. Radiation therapy field sizes and doses were similar to those recommended for early-stage Hodgkin's disease patients treated with radiation therapy alone. The 5-year actuarial freedom from relapse (FFR) and survival following retreatment were 48% and 69%, respectively. Twelve patients are currently disease-free 12 to 172 months following retreatment. Wide-field radiation therapy alone or with additional chemotherapy should be considered for patients with advanced Hodgkin's disease who relapse in nodal sites after initial combination chemotherapy.

Cancer ◽  
1976 ◽  
Vol 37 (4) ◽  
pp. 1625-1632 ◽  
Author(s):  
William C. Cham ◽  
Charlotte T. C. Tan ◽  
Alvaro Martinez ◽  
Philip R. Exelby ◽  
Melvin Tefft ◽  
...  

2007 ◽  
Vol 25 (3) ◽  
pp. 332-337 ◽  
Author(s):  
Sarah S. Donaldson ◽  
Michael P. Link ◽  
Howard J. Weinstein ◽  
Shesh N. Rai ◽  
Sam Brain ◽  
...  

Purpose To evaluate outcome and assess complications in children and adolescents with low-risk Hodgkin's disease treated with vinblastine, doxorubicin, methotrexate, and prednisone (VAMP) chemotherapy and low-dose, involved-field radiation therapy (IFRT). Patients and Methods One hundred ten children with low-risk Hodgkin's disease were treated with four cycles of VAMP and 15 Gy IFRT for those who achieved a complete response (CR) or 25.5 Gy for those with a partial response after two cycles of VAMP. Results With median follow-up of 9.6 years (range, 1.7 to 15.0), 5- and 10-year overall survival were 99.1% and 96.1%, respectively, and 5-and 10-year event-free survival (EFS) were 92.7% and 89.4%. Factors contributing to 10-year EFS were: early CR (P = .02), absence of B symptoms (P = .01), lymphocyte predominant histologic subtype (P = .04), and less than three initial sites of disease (P = .02). Organ toxicity has been limited to correctable hypothyroidism in 42% of irradiated patients, and one case of cardiac dysfunction. Seventeen healthy babies have been born to 106 survivors. There have been two malignant tumors: one thyroid cancer within the radiation therapy field and one Ewing's sarcoma outside the radiation therapy field. Conclusion Risk-adapted, combined-modality therapy using VAMP chemotherapy with radiation is effective and well tolerated. Pediatric patients with low-risk Hodgkin's disease can be cured with therapy without an alkylating agent, bleomycin, etoposide, or high-dose, extended-field radiotherapy. Thus, these children are expected to retain normal fertility, organ function, and be at low risk of a second malignant tumor.


1989 ◽  
Vol 17 (1) ◽  
pp. 9-14 ◽  
Author(s):  
German A. Gomez ◽  
Ramachandra M. Krishnamsetty ◽  
Tin Han ◽  
Edward S. Henderson

1995 ◽  
Vol 31 (2) ◽  
pp. 227-236 ◽  
Author(s):  
Michael Barton ◽  
John Boyages ◽  
Elizabeth Crennan ◽  
Sidney Davis ◽  
Richard J. Fisher ◽  
...  

Cancer ◽  
1993 ◽  
Vol 72 (1) ◽  
pp. 207-212 ◽  
Author(s):  
Minoru Uematsu ◽  
Nancy J. Tarbell ◽  
Barbara Silver ◽  
C. Norman Coleman ◽  
David S. Rosenthal ◽  
...  

Cancer ◽  
1991 ◽  
Vol 68 (9) ◽  
pp. 1869-1873 ◽  
Author(s):  
A. L. Zietman ◽  
R. M. Linggood ◽  
A. R. Brookes ◽  
K. Convery ◽  
A. Piro

Sign in / Sign up

Export Citation Format

Share Document